Audio Journal of Oncology Podcast

By Audio Medica News

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world... more

FAQs about Audio Journal of Oncology Podcast:

How many episodes does Audio Journal of Oncology Podcast have?

The podcast currently has 119 episodes available.

Audio Journal of Oncology Podcast episodes:

April 17, 2018 Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation
BARCELONA—A multicenter nationwide Italian study of patients with ductal carcinoma in situ (DCIS) treated with breast conservative surgery (BCS) and whole breast radiotherapy (RT) has updated risk criteria to help women opt for gentler treatments and avoid toxicities from overtreatment.
At the 2018 European Breast Cancer Conference Icro Meattini MD, Consultant Clinical Oncologist in the Radiation Oncology Department at Azienda Ospedaliero-Universitaria Careggi, University of Florence, Italy said: “A diagnosis of DCIS can be frightening but also confusing. Although we know that very few patients will go on to develop invasive cancer we don’t know which ones they will be and so we offer treatments such as surgery and radiotherapy and sometimes hormone therapy.” He discusses the findings of his study with the Audio Journal of Oncology.
...more
0min
April 16, 2018 Breast Cancer: Combined Risk Assessment Prompts Treatment De-Escalation
BARCELONA—Not only was breast conserving therapy safer than mastectomy for most low-risk patients in the large randomized EORTC 10041/BIG 03-04 MINDACT trial reported at the 2018 European Breast Cancer Conference but also many patients could be advised to avoid chemotherapy and radiotherapy altogether after assessing their risk as "low" by using a combination of clinical and genetic risk scores, the study concluded.
Emiel Rutgers MD, PhD, a surgeon at the Netherlands Cancer Institute and professor of surgical oncology at the University of Amsterdam said MINDACT found an overall five-year loco-regional recurrence rate of only 2.1 per cent in patients treated conservatively and 2.5 per cent in those who had mastectomy. Tumor size and grade were the only independent risk factors and the results provided “the opportunity to prospectively study de-escalation of radiotherapy in women with low-risk early breast cancer”. He discussed his study and the clinical implications for the Audio Journal of Oncology.
...more
0min
March 30, 2018 Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY
BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2 mutation the procedure did not improve overall survival even though it reduced their risk of breast cancer in the next ten years. These findings were reported at the 2018 European Breast Cancer Conference from an analysis of the Netherlands national Hereditary Breast and Ovarian Cancer Netherlands (HEBON) database.
First author Annette Hemskerk-Gerritsen PhD, a post-doctoral researcher at Erasmus Medical Center in Rotterdam, discusses the clinical implications of the study for the Audio Journal of Oncology.
...more
5min
March 29, 2018 Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY
BARCELONA—Healthy women with BRCA1 mutations who opted for bilateral prophylactic mastectomy had their lives prolonged in comparison with similar women who did not. But in healthy women with the BRCA2 mutation the procedure did not improve overall survival even though it reduced their risk of breast cancer in the next ten years. These findings were reported at the 2018 European Breast Cancer Conference from an analysis of the Netherlands national Hereditary Breast and Ovarian Cancer Netherlands (HEBON) database
“From previous studies we already know that by [having] prophylactic mastectomy you reduce the risk of breast cancer very strongly, but it was not proven that as a consequence survival was better,” said first author Annette Hemskerk-Gerritsen PhD, a post-doctoral researcher at Erasmus Medical Center in Rotterdam, talked about the study findings she presented at the conference for the Audio Journal of Oncology
Annette Heemskerk-Gerritsen AJO PRODUCTION MASTER
...more
5min
March 28, 2018 Polygenic Risk Scores Could Help Predict Second Primary Breast Cancers—AUDIO JOURNAL OF ONCOLOGY
BARCELONA—Patients treated for BRCA-associated breast cancers could be given more accurate estimates of the risk for developing second primaries of the contralateral breast by combining polygenic risk scores (PRS) with standard risk factors if study findings reported at the 2018 European Breast Cancer Conference are validated.
The AUDIO JOURNAL OF ONCOLOGY heard from lead author Alexandra van den Broek PhD, a genetic epidemiologist from the Netherlands Cancer Institute in Amsterdam, how the predictive power of PRSs for a first primary breast cancer in the general population and for BRCA 1 and 2 mutation carriers could also extend to forecasting second primaries of the contralateral breast enabling women to make more informed decisions about their on-going treatment options.
Isabel T. Rubio MD PhD, co-chair of the 11th European Breast Cancer Conference and Director of the Breast Surgical Unit at Clinica Universidad de Navarra, in Madrid, Spain who was not involved in the research said: “Facing a diagnosis of breast cancer and carrying a BRCA mutation is overwhelming for many women. New information on the individual risks of developing a contralateral breast cancer in this population will help in the decision-making process on preventive surgery or intensive follow up. Research like this brings new information to help with these difficult decisions.”
Abstract no: 7:
“The association between Polygenic Risk Scores and contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: analyses in the CIMBA consortium”
https://www.ecco-org.eu/Global/News/EBCC/EBCC11/03/Risk-of-a-second-breast-cancer-can-be-better-quantified-in-women-carrying-a-BRCA-mutation
Read Peter Goodwin's article in ONCOLOGY TIMES

...more
0min
February 05, 2018 Randomized Study Confirms Rivaroxaban Oral Alternative For Cancer Thromboembolism
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe and effective alternative strategy to standard treatment with the low molecular weight heparin dalteparin for avoiding recurrences of venous thromboembolism (VTE) in selected patients with cancer. The findings were reported at the 2017 meeting of the American Society of Hematology. Abstract 625: Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D Pilot Trial
“We found recurrence rates with dalteparin at six months were 11 per cent. With rivaroxaban the recurrence rates were four per cent,” said lead author Annie Young PhD, Professor of Nursing at Warwick Clinical Trials Unit in Warwick University Medical School’s Cancer Research Centre, UK. “Definitely we found that the rivaroxaban recurrence rates at six months were lower than dalteparin.”
READ MORE IN ONCOLOGY TIMES
...more
15min
February 05, 2018 Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism
ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe and effective alternative strategy to standard treatment with the low molecular weight heparin dalteparin for avoiding recurrences of venous thromboembolism (VTE) in selected patients with cancer. The findings were reported at the 2017 meeting of the American Society of Hematology. Abstract 625: Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D Pilot Trial
“We found recurrence rates with dalteparin at six months were 11 per cent. With rivaroxaban the recurrence rates were four per cent,” said lead author Annie Young PhD, Professor of Nursing at Warwick Clinical Trials Unit in Warwick University Medical School’s Cancer Research Centre, UK. “Definitely we found that the rivaroxaban recurrence rates at six months were lower than dalteparin.”
READ MORE IN ONCOLOGY TIMES
...more
15min
January 26, 2018 Oral Anticoagulant Edoxaban Alternative for Cancer-Related Thromboembolism
ATLANTA— In patients with a variety of cancers oral therapy with edoxaban—a direct oral anticoagulant (DOAC)—was just as effective and safe in terms of the risks of recurrent venous thromboembolism (VTE) and bleeding as injections with the low molecular weight heparin (LMWH) dalteparin in the multinational randomized Hokusai VTE-Cancer Study reported at the 2017 American Society of Hematology annual meeting.
LBA-6 A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study
“[The] findings show that the edoxaban treatment is non-inferior to the low molecular weight heparin therapy,” said lead author Gary E. Raskob PhD, Dean of the College of Public Health and Professor of Medicine and Epidemiology at the University of Oklahoma in Oklahoma City.
READ MORE from the American Society of Hematology Meeting in Oncology Times.

...more
10min
January 19, 2018 Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia
ATLANTA—Adding anti-BCL-2 therapy with the small-molecule drug venetoclax (VEN) to standard low-dose cytarabine (LDAC) chemotherapy tripled response rates over historical comparators and extended survival in older patients with acute myeloid leukemia (AML) who were ineligible for intensification of their chemotherapy in a phase 1/2 study reported at the 2017 American Society of Hematology annual meeting.
ABSTRACT 890 Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes
“With this new combination we seem to achieve very high complete response rates. We achieve response quickly—which means that patients have better quality of life, potentially, and less risk of fatal infections and also less need for blood transfusions and supportive care,” said lead study author Andrew Wei MBBS PhD FRACP FRCPA, a clinical hematologist and head of leukemia research at the Alfred Hospital in Melbourne, Australia.
READ THE ARTICLE IN ONCOLOGY TIMES
...more
5min
April 20, 2017 Cabozantinib Better for VEGF Resistant Metastatic Renal Cell Carcinoma

MILAN, Italy—The first choice of therapy for patients with metastatic kidney cancer who have failed VEGF therapy has changed according to experts at the 2016 European Multidisciplinary Meeting on Urological Cancers (EMUC) who assessed phase 3 study data on two different agents—each of which showed clinically meaningful improvements to outcomes.

“There is a new treatment algorithm for individuals who have failed VEGF-targeted therapy,” said Thomas Powles, MBBS MRCP MD, Director of Barts Cancer Centre at St Bartholemews Hospital in London, UK.

“Both the ESMO and EAU guidelines are [now] supporting nivolumab and cabozantinib rather than—[as] previously—supporting axitinib and everolimus.”

He based his comments on observations from the METEOR and CheckMate 025 studies which found that therapy with cabozantinib or nivolumab improved overall survival compared to everolimus.
Peter Goodwin discusses the details of the METEOR findings with him.
...more
0min

FAQs about Audio Journal of Oncology Podcast:

How many episodes does Audio Journal of Oncology Podcast have?

The podcast currently has 119 episodes available.

More shows like Audio Journal of Oncology Podcast

Journal of Clinical Oncology (JCO) Podcast

40 Listeners

Up First from NPR

56,080 Listeners

Yale Cancer Answers

20 Listeners

Share Audio Journal of Oncology Podcast

Sign up to save your podcasts

Audio Journal of Oncology Podcast

FAQs about Audio Journal of Oncology Podcast:

How many episodes does Audio Journal of Oncology Podcast have?

Audio Journal of Oncology Podcast episodes:

FAQs about Audio Journal of Oncology Podcast:

How many episodes does Audio Journal of Oncology Podcast have?

More shows like Audio Journal of Oncology Podcast

Journal of Clinical Oncology (JCO) Podcast

Up First from NPR

Yale Cancer Answers